- Home
- CALC
CALC
CalciMedica Inc.
as 05-20-2024 11:33am EST
$.
+$.
+.%
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.
| Founded: | N/A | Country: | United States |
| Employees: | 14 | City: | LA JOLLA |
| Market Cap: | 60.1M | IPO Year: | 2023 |
| Target Price: | N/A | AVG Volume (30 days): | N/A |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | N/A | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Stock Insider Trading Activity of CalciMedica Inc. (CALC)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Roberts Eric W | CALC | CHIEF BUSINESS OFFICER | Apr 1 '24 | Buy | $3.90 | 746 | $2,909.40 | 36,640 | SEC Form 4 |
| Roberts Eric W | CALC | CHIEF BUSINESS OFFICER | Apr 1 '24 | Buy | $3.90 | 3,254 | $12,690.60 | 39,894 | SEC Form 4 |
| Sanderling Venture Partners VI LP | CALC | 10% Owner | Jan 23 '24 | Buy | $3.70 | 28,744 | $106,410.29 | 30,292 | SEC Form 4 |
| Sanderling Venture Partners VI LP | CALC | 10% Owner | Jan 23 '24 | Buy | $3.70 | 3,920 | $14,511.84 | 21,602 | SEC Form 4 |
| Sanderling Venture Partners VI LP | CALC | 10% Owner | Jan 23 '24 | Buy | $3.70 | 13,184 | $48,807.17 | 27,609 | SEC Form 4 |
| Sanderling Venture Partners VI LP | CALC | 10% Owner | Jan 23 '24 | Buy | $3.70 | 51,032 | $188,920.46 | 114,260 | SEC Form 4 |
| Sanderling Venture Partners VI LP | CALC | 10% Owner | Jan 23 '24 | Buy | $3.70 | 194,472 | $719,935.34 | 435,148 | SEC Form 4 |
| Sanderling Venture Partners VI LP | CALC | 10% Owner | Jan 23 '24 | Buy | $3.70 | 144,676 | $535,590.55 | 727,433 | SEC Form 4 |
| Sanderling Venture Partners VI LP | CALC | 10% Owner | Jan 23 '24 | Buy | $3.70 | 243,356 | $900,903.91 | 946,744 | SEC Form 4 |
| MIDDLETON FRED A | CALC | Director10% Owner | Jan 23 '24 | Buy | $3.70 | 243,356 | $900,903.91 | 946,744 | SEC Form 4 |
| MIDDLETON FRED A | CALC | Director10% Owner | Jan 23 '24 | Buy | $3.70 | 144,676 | $535,590.55 | 727,433 | SEC Form 4 |
| MIDDLETON FRED A | CALC | Director10% Owner | Jan 23 '24 | Buy | $3.70 | 194,472 | $719,935.34 | 435,148 | SEC Form 4 |
| MIDDLETON FRED A | CALC | Director10% Owner | Jan 23 '24 | Buy | $3.70 | 51,032 | $188,920.46 | 114,260 | SEC Form 4 |
| MIDDLETON FRED A | CALC | Director10% Owner | Jan 23 '24 | Buy | $3.70 | 13,184 | $48,807.17 | 27,609 | SEC Form 4 |
| MIDDLETON FRED A | CALC | Director10% Owner | Jan 23 '24 | Buy | $3.70 | 3,920 | $14,511.84 | 21,602 | SEC Form 4 |
| MIDDLETON FRED A | CALC | Director10% Owner | Jan 23 '24 | Buy | $3.70 | 28,744 | $106,410.29 | 30,292 | SEC Form 4 |
| WILSON ROBERT N | CALC | Director | Dec 11 '23 | Buy | $3.30 | 506 | $1,669.80 | 182,161 | SEC Form 4 |
| Leheny A. Rachel | CALC | Chief Executive Officer | Nov 6 '23 | Buy | $3.12 | 2,440 | $7,614.75 | 16,840 | SEC Form 4 |
| Leheny A. Rachel | CALC | Chief Executive Officer | Nov 3 '23 | Buy | $2.85 | 5,000 | $14,250.00 | 14,400 | SEC Form 4 |
| Hebbar Sudarshan | CALC | Chief Medical Officer | Nov 3 '23 | Buy | $2.74 | 36,000 | $98,600.40 | 46,000 | SEC Form 4 |
Latest CalciMedica Inc. News
CALC Breaking Stock News: Dive into CALC Ticker-Specific Updates for Smart Investing
PR Newswire
7 days ago
CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
PR Newswire
13 days ago
CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024
PR Newswire
a month ago
CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis
PR Newswire
2 months ago
CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates
PR Newswire
2 months ago
CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference
PR Newswire
3 months ago
CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference
PR Newswire
3 months ago
CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury
PR Newswire
3 months ago